ALIMTA (pemetrexed for injection) [package insert]. Indianapolis, IN: Eli Lilly and Company; Langer CJ, et al. Lancet Oncol. ;17(11) Learn how ALIMTA may help treat advanced nonsquamous non-small cell lung cancer. ALIMTA and carboplatin (carbo) is approved by the FDA to be used with an the FDA in combination with carboplatin (another chemotherapy drug) and. Read all of this leaflet carefully before you start receiving this medicine because it contains important information for you. -. Keep this leaflet. You may need to.
|Published (Last):||19 October 2011|
|PDF File Size:||3.72 Mb|
|ePub File Size:||6.24 Mb|
|Price:||Free* [*Free Regsitration Required]|
ALIMTA is contraindicated in patients who have a history of severe hypersensitivity reaction to pemetrexed. Tell your healthcare provider right away if you develop blisters, skin sores, skin peeling, or painful sores, or ulcers in your mouth, nose, throat or genital area.
ALIMTA® (Pemetrexed) and Pharmacokinetics
Severe vomiting or diarrhea can lead to loss of fluids dehydration which may cause kidney problems to become worse. There is no information regarding the presence of pemetrexed or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.
Tell your healthcare provider right away if you get any new or worsening symptoms of shortness of breath, cough, or fever. Based on Kaplan-Meier estimation. Monitor patients for inflammation or blistering in areas of previous radiation treatment. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Tell your healthcare provider right away if you have any signs of infection, fever, bleeding, or severe tiredness during your treatment with ALIMTA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Withhold ALIMTA for acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, or fever pending diagnostic evaluation. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Low blood cell counts. Indications and Important Safety Information. Adverse reactions observed in pediatric patients studied were similar to those observed in adults. Your healthcare provider may change your dose of ALIMTA, delay treatment, or stop treatment if you have certain side effects. If you are allergic to pemetrexed, tell your doctor because you should not receive it. Kidney problems, including kidney failure. Obtain a complete blood count at the beginning of each cycle.
Indications and Important Safety Information. Advise males with female partners of reproductive potential to use effective contraception during treatment with ALIMTA and for 3 months after the final dose.
Based on findings from animal studies and its mechanism of action, ALIMTA can cause fetal harm when administered to a pregnant woman.
Your healthcare provider will prescribe a medicine called a corticosteroid for you to take 2 times a day for 3 days, beginning the day before each treatment with ALIMTA. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Folic acid and vitamin B 12 supplementation should be continued during treatment and for packagf days after the last dose of ALIMTA as they may reduce the severity of treatment-related hematologic and packafe toxicities.
Langer CJ, et al. ALIMTA is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma MPM whose disease is unresectable or who are otherwise not candidates for curative surgery. This indication is approved under accelerated approval based on tumor response rate and progression-free survival. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Packate concomitant ibuprofen use cannot be avoided, monitor patients more frequently for ALIMTA adverse reactions, including myelosuppression, renal, and gastrointestinal toxicity. ALIMTA can aalimta severe myelosuppression resulting in a requirement for transfusions and which may lead to neutropenic infection.
Advise pregnant women of the potential risk to the fetus. The infusion is given over 10 minutes. The incidences of Grade anemia, fatigue, thrombocytopenia, hypertension, and neutropenia were higher in patients 65 years of age and older as compared to younger patients: Scagliotti GV, et al. It is very important to take folic acid by mouth and receive vitamin B 12 injections from your healthcare provider during your treatment with ALIMTA to lower your risk of harmful side effects.
Accessed June 27, Tell your imsert provider right away if you have a decrease in amount of urine.
To view the most recent and complete version of the guidelines, go online to NCCN. Advise females of reproductive potential to use effective contraception during treatment with ALIMTA and for 6 months after the final dose.
Overall response rate a ORR: ALIMTA is indicated as a single agent for the maintenance treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. Males of Reproductive Potential: Call your doctor for medical advice about side effects. Patients with Renal Impairment: Ibuprofen increases exposure AUC of pemetrexed.
Your healthcare provider will do a blood test to check your blood cell counts regularly during your treatment with ALIMTA. Tell your healthcare provider if you get swelling, blistering, or a rash that looks like a sunburn in an area that was previously treated with radiation. Like cisplatin, carboplatin contains platinum. It is not known if these effects are reversible.
Advanced NS NSCLC Treatment | ALIMTA (pemetrexed for injection)
For more information, ask your healthcare provider or pharmacist. Go to data for additional indications. The risk of myelosuppression is increased in patients who do not receive vitamin supplementation.
Low blood cell counts can be severe, including low white blood cell counts neutropenialow platelet counts thrombocytopeniaand low red blood cell counts anemia.